Creo Medical Group PLC (LON:CREO - Get Free Report)'s share price shot up 14.7% during mid-day trading on Friday . The stock traded as high as GBX 20 ($0.25) and last traded at GBX 19.50 ($0.25). 1,732,157 shares changed hands during mid-day trading, an increase of 139% from the average session volume of 723,984 shares. The stock had previously closed at GBX 17 ($0.21).
Creo Medical Group Stock Up 14.7 %
The stock has a market cap of £70.55 million, a P/E ratio of -325.00 and a beta of 0.86. The company's fifty day moving average price is GBX 17.89 and its 200-day moving average price is GBX 26.02. The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24.
Insiders Place Their Bets
In other Creo Medical Group news, insider Richard John Rees bought 98,000 shares of Creo Medical Group stock in a transaction on Thursday, October 24th. The shares were acquired at an average price of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,632.40). Also, insider Kevin Crofton bought 2,916,666 shares of the firm's stock in a transaction dated Monday, October 21st. The shares were acquired at an average price of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($879,728.34). Insiders bought a total of 4,193,666 shares of company stock valued at $92,002,984 over the last 90 days. Insiders own 22.43% of the company's stock.
About Creo Medical Group
(
Get Free Report)
Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.
Further Reading
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
